Does DAROLUTAMIDE Cause Malignant neoplasm progression? 37 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Malignant neoplasm progression have been filed in association with DAROLUTAMIDE (NUBEQA). This represents 1.1% of all adverse event reports for DAROLUTAMIDE.
37
Reports of Malignant neoplasm progression with DAROLUTAMIDE
1.1%
of all DAROLUTAMIDE reports
4
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DAROLUTAMIDE?
Of the 37 reports, 4 (10.8%) resulted in death, 3 (8.1%) required hospitalization, and 1 (2.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DAROLUTAMIDE. However, 37 reports have been filed with the FAERS database.
What Other Side Effects Does DAROLUTAMIDE Cause?
Fatigue (384)
Death (361)
Hot flush (203)
Asthenia (173)
Prostatic specific antigen increased (156)
Off label use (133)
Neuropathy peripheral (127)
Diarrhoea (122)
Dizziness (122)
Rash (116)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DAROLUTAMIDE Alternatives Have Lower Malignant neoplasm progression Risk?
DAROLUTAMIDE vs DARUNAVIR
DAROLUTAMIDE vs DARUNAVIR ETHANOLATE
DAROLUTAMIDE vs DARUNAVIR\RITONAVIR
DAROLUTAMIDE vs DASABUVIR
DAROLUTAMIDE vs DASABUVIR\OMBITASVIR HEMINONAHYDRATE\PARITAPREVIR\RITONAVIR